NCT00566449View on ClinicalTrials.gov

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Placebo

one dose daily for 4 weeks

DRUG

JNJ-31001074

10 mg daily for 4 weeks

DRUG

JNJ-31001074

30 mg daily for 4 weeks

Trial Locations (21)

Unknown

Irvine

Lafayette

San Francisco

Bradenton

Fort Myers

Orlando

South Miami

Eagle

Libertyville

Overland Park

Boston

Farmington

Chapel Hll

Raleigh

Dayton

Portland

Media

Austin

Houston

Herndon

Seattle

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00566449 - A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder. | Biotech Hunter | Biotech Hunter